CANADA STOCKS-TSX steady as U.S. action in Iraq weighs
* TSX up 4.75 points, or 0.03 percent, at 15,123.18 * Six of 10 main index sectors decline * Avigilon tumbles after quarterly report * Tekmira surges on regulatory clearance for drug By John Tilak TORONTO, Aug 8 (Reuters) - Canada's main stock index was little changed in choppy trading on Friday as a U.S. decision to conduct air strikes in Iraq gave the commodities sector a boost but weighed on the broader market. U.S. warplanes struck Iraq for the first time since American troops pulled out in 2011, attacking Islamist fighters advancing toward the Kurdish region. Investors also weighed the significance of data showing that China's exports lifted its trade surplus to a record in July. The benchmark TSX has been hit over the past week by concerns about Ukraine, Israel and Iraq. It is down about 2.7 percent since touching a record high last week. "These problems haven't gotten away and if anything they seem to be worsening," said Colin Cieszynski, senior market analyst at CMC Markets Canada, who expects a high level of volatility in the next three months. The Toronto Stock Exchange's S&P/TSX composite index was up 4.75 points, or 0.03 percent, at 15,123.18. Six of the 10 main sectors on the index were in the red. Financials, the index's most heavily weighted sector, fell 0.7 percent. Bank of Nova Scotia shed 1 percent to C$71.48, and Toronto Dominion Bank lost 0.9 percent to C$55.45. Shares of energy producers were up 0.4 percent, with Canadian Natural Resources Ltd rising 0.7 percent to C$45.12 and Talisman Energy Inc jumping 1.9 percent to C$11.57. The gold-mining sector climbed with the bullion price, which was higher in choppy trade. Barrick Gold Corp gained 2.5 percent to C$20.68, and Goldcorp Inc advanced 0.8 percent to C$31.13. In corporate news, shares of Avigilon Corp tumbled 14 percent to C$21.40 after the maker of video surveillance cameras reported quarterly results late on Thursday. Tekmira Pharmaceuticals Corp jumped 19 percent, to C$18.50, after U.S. regulators partially lifted a hold on the company's experimental Ebola drug to enable its potential use on humans infected with the virus. (Editing by Tom Brown)
© Thomson Reuters 2017 All rights reserved.